Related Experiment Videos
Improved survival of patients with cystic fibrosis
Insights
Cystic fibrosis (CF) patient survival rates are improving, with many reaching adulthood and maintaining good lung health. Recent management strategies show enhanced long-term outcomes for individuals with CF.
Area of Science:
- Pediatric Medicine
- Pulmonology
- Gastroenterology
Background:
- Cystic Fibrosis (CF) is a genetic disorder affecting multiple organs.
- Long-term survival and quality of life in CF patients have historically been challenges.
- Improved medical management aims to enhance outcomes for CF patients.
Purpose of the Study:
- To review the survival rates of cystic fibrosis patients born in and after 1958.
- To evaluate the impact of recent management strategies on patient longevity and health.
- To assess the current lung health status of patients under care.
Main Methods:
- Retrospective review of 320 cystic fibrosis patients managed at a tertiary pediatric hospital.
- Analysis of survival data based on age at follow-up and years since diagnosis.
- Assessment of lung disease severity in currently managed patients.
Main Results:
- 80% of patients survived to 11 years, and 64% to 18 years.
- For patients managed between 1973-1977, 91% survived to 12 years and 80% to 17 years.
- 44% of current patients have no significant lung disease; only 9% have advanced disease.
Conclusions:
- Significant improvements in cystic fibrosis patient survival have been observed.
- Modern management protocols are associated with better long-term outcomes and lung health.
- Continued advancements in care are crucial for enhancing the quality of life for CF individuals.
Abstract:
The survival of 320 patients, who were born in and after 1958 with cystic fibrosis and managed by the Departments of Thoracic Medicine and Gastroenterology, Royal Children's Hospital, Melbourne, is reviewed. Eighty per cent of patients survived to 11 years of age, and 64% to 18 years. Of patients managed between 1973 and 1977, 91% survived to 12 years of age, and 80% to 17 years of age. In the same period, 79% of patients survived for 16 years after diagnosis. Forty-four per cent of the 240 patients currently being managed have no significant permanent lung disease, and only 9% have advanced disease.